RxDoctor Payments Data

Shaun Laurie, MD

Internal Medicine · Tallahassee, FLNPI 1952344285

Payments from drug & device makers

$7,201in general payments, 2019–2025

Across 439 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Astellas Pharma US Inc$727
  • Pfizer$484
  • Lilly USA, LLC$424
  • Novartis$381
  • AstraZeneca$333
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$6,91696%
  • Education$2854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,201 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$789,511
Medicare patients
665
Services billed
7,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,394$545,905
JanuviaSitagliptin Phosphate793$366,173
JardianceEmpagliflozin409$197,661
EntrestoSacubitril/Valsartan219$96,070
MounjaroTirzepatide85$93,963
AptiomEslicarbazepine Acetate101$76,737
XareltoRivaroxaban150$69,050
TradjentaLinagliptin249$68,184
FarxigaDapagliflozin Propanediol101$58,497
OzempicSemaglutide57$54,623
RybelsusSemaglutide42$52,575
MyrbetriqMirabegron153$48,008
FanaptIloperidone14$47,513
BiktarvyBictegrav/Emtricit/Tenofov Ala11$46,293
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog306$42,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$484$545,9051,394 claims
MerckJanuvia, Janumet, Janumet Xr$125$414,370874 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$318$289,740690 claims
Lilly USA, LLCMounjaro, Trulicity$424$128,878129 claims
Johnson & JohnsonXarelto, Invega Sustenna$109$111,064163 claims
Novo NordiskOzempic, Rybelsus$1,077$107,19899 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$139$98,571187 claims
NovartisEntresto$381$96,070219 claims
AbbVieLinzess, Creon$305$80,998100 claims
AstraZenecaFarxiga, Brilinta$333$78,031167 claims
Sunovion Pharmaceuticals Inc.Aptiom$243$76,737101 claims
Astellas Pharma US IncMyrbetriq$727$48,008153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →